Certain Options of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.
November 31, 2023
Share
Certain Options of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023. These Options will be under lockup for 90 days starting from 3-AUG-2023 to 1-NOV-2023.
Details:
The company's executive officers, directors and certain holders of 5% or more of the outstanding shares of common stock expect to enter into lock up agreements with prior to the commencement of this offering pursuant to which each of these persons or entities, for a period of ninety (90) days from the effective date of the registration statement of which this prospectus forms a part, without its prior consent, agree not to offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act, any shares of common stock or securities convertible, or exercisable into, shares of common stock.
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
BIO-PATH HOLDINGS, INC. 
